Inhibition of inducible nitric oxide synthase by β-lapachone in rat alveolar macrophages and aorta

British Journal of Pharmacology

Volumn 126, Issue 3, 1999, Pages 746-750

  Liu, Shing Hwa ^a   Tzeng, Huei Ping ^a   Kuo, Min Liang ^a   Lin Shiau, Shoei Yn ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

lapachone; Inducible NO synthase; Lipopolysaccharide; Nitric oxide

Indexed keywords

BETA LAPACHONE; DNA TOPOISOMERASE INHIBITOR; LIPOPOLYSACCHARIDE; NITRIC OXIDE SYNTHASE; NITRITE; PHENYLEPHRINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; ENZYME INHIBITION; LUNG ALVEOLUS MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; RAT; THORACIC AORTA;

ANIMALS; AORTA, THORACIC; CELL LINE; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; HUMANS; LIPOPOLYSACCHARIDES; MACROPHAGES, ALVEOLAR; MALE; MUSCLE CONTRACTION; NAPHTHOQUINONES; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE I; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; NITRITES; PHENYLEPHRINE; RATS; RATS, WISTAR; VASOCONSTRICTOR AGENTS;

EID: 0033028722     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702341     Document Type: Article

References (26)

1. BALOCH, Z., COHEN, S. & COFFMAN, F.D. (1990). Synergistic interactions between tumor necrosis factor and inhibitors of DNA topoisomerase I and II. J. Immunol., 145, 2908-2913.
2. BOGLE, R.G., SOO, S.-C., WHITLEY, G.ST.J., JOHNSTONE, A.P. & VALLANCE, P. (1994). Effects of anti-fungal imidazoles on mRNA levels and nitric oxide synthesis in cultured murine macrophages. Br. J. Pharmacol., 105, 919-923.
3. BOGLE, R.G. & VALLANCE, P. (1996). Functional effects of econazole on inducible nitric oxide synthase: production of a calmodulin-dependent enzyme. Br. J. Pharmacol., 117, 1053-1058.
4. BRAIN, J.D. & FRANK, R. (1968). Recovery of free cells from rat lungs by repeated washings. J. Appl. Physiol., 25, 63-69.
5. CHAU, Y.P., SHIAH, S.G., DON, M.J. & KUO, M.L. (1998). Involvement of hydrogen peroxide in topoisomerase inhibitor β-lapachone-induced apoptosis and differentiation in human leukaemia cells. Free Radical Biol. Med., 24, 660-670.
6. GONCALVES, A.M., VASCONELLOS, M.E., DECOMPO, R., CRUZ, N.S., SOUZA, W.R. & LEON, W. (1980). Evaluation of the toxicity of 3-ally-beta-lapachone against Trypanosoma cruzi blood-stream forms. Mol. Biochem. Parasitol., 1, 167-176.
7. 15N]nitrate in biological fluids. Anal. Biochem., 126, 131-138.
8. GUIRAUD, P., STEIMAN, R., CAMPOS-TAKAKI, G.M., SEIGLE-MURANDI, F. & SIMEN DE BUOCHBERG, M. (1994). Comparison of antibacterial and antifungal activities of lapachol and beta-lapachone. Planta Med., 60, 373-374.
9. HIBBS, J.B.J., TAINTOR, R.R. & VAVRIN, F. (1987). Macrophage cytotoxicity: role for L-arginine deiminase and imino nitrogen oxidation to nitrite. Science, 235, 473-476.
10. JOLY, G.A., AYRES, M. & KILBOURN, R.G. (1997). Potent inhibition of inducible nitric oxide synthase by geldanamycin, a tyrosine kinase inhibitor, in endothelial, smooth muscle cells, and in rat aorta. FEBS Lett., 403, 40-44.
11. KOBZIK, L., REID, M.B., BREDT, D.S. & STAMLER, J.S. (1994). Nitric oxide in skeletal muscle. Nature, 372, 546-548.
12. KRETZSCHMAR, M., MEISTERERNST, M. & ROEDER, R.G. (1993). Identification of human DNA topoisomerase I as a cofactor for activator-dependent transcription by RNA polymerase II. Proc. Natl. Acad. Sci. U.S.A., 90, 11508-11512.
13. LI, C.J., AVERBOUKH, L. & PARDEE, A.B. (1993). Beta-lapachone, a novel DNA topoisomerase I inhibitor with a mode of action different from camptothecin. J. Biol. Chem., 268, 22463-22468.
14. LI, C.J., WANG, C. & PARDEE, A.B. (1995). Induction of apoptosis by beta-lapachone in human prostate cancer cells. Cancer Res., 55, 3712-3715.
15. LOWENSTEIN, C.J. & SNYDER, S.H. (1992). Nitric oxide, a novel biologic messenger. Cell, 70, 705-707.
16. LOWRY, O.H., ROSENBROUGH, N.J., FARR, A.L. & RANDALL, R.J. (1951). Protein measurement with the Folin phenol reagent. J. Biol. Chem., 193, 265-275.
17. MONCADA, S., PALMER, R.M.J. & HIGGS, E.A. (1991). Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol. Rev., 43, 109-142.
18. MORRIS, S.M. & BILLIAR, T.R. (1994). New insights into the regulation of inducible nitric oxide synthesis. Am. J. Physiol., 266, E829-E839.
19. MOSMANN, T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65, 55-63.
20. MURPHY, S., SIMMONS, M.L., AGULLO, L., GARCIA, A., FEINSTEIN, D.L., GALEA, E., REIS, D.J., MINC-GOLOMB, D. & SCHWARTZ, J.P. (1993). Synthesis of nitric oxide in CNS glial cells. Trend Neurosci., 16, 323-328.
21. PLANCHON, S.M., WUERZBERGER, S., FRYDMAN, B., WITIAK, D.T., HUTSON, P., CHURCH, D.R., WILDING, G. & BOOTHMAN, D.A. (1995). Beta-lapachone-mediated apoptosis in human promyelocytic leukemis (HL-60) and human prostate cancer cells: A p53-independent response. Cancer Res., 55, 3706-3711.
22. RADOMSKI, M.W., PALMER, R.M.J. & MONCADA, S. (1990). Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc. Natl. Acad. Sci. U.S.A., 87, 10043-10047.
23. SCHAFFNER-SABBA, K., SCHMIDT-RUPPIN, K.H., WEHRIL, W., SCHUERCH, A.R. & WASLEY, J.W.F. (1984). Beta-lapachone: synthesis of derivatives and activities in tumor models. J. Med. Chem., 27, 990-994.
24. STUEHR, D.J. & NATHAN, C.F. (1989). Nitric oxide: a macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J. Exp. Med., 169, 1543-1555.
25. SUZUKI, H., YAMASHITA, M., LEE, J.C., KATAOKA, T., MAGAE, J. & NAGAI, K. (1996). Immunosuppressive activity of streptonigrin in vitro and in vivo. Biosci. Biotech. Biochem., 60, 789-793.
26. VALLANCE, P. & MONCADA, S. (1993). The role of endogenous nitric oxide in septic shock. New Horizons, 1, 77-86.